National Toll Free Hotline for PET Scans Debuts to Meet Growing Demand for Alzheimer's Diagnosis

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Merrill L.Inc	LSE:MLRI	London	Ordinary Share	IE0031168291	INC SHS NPV

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Merrill L.Inc (LSE:MLRI)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Merrill L.Inc Charts.

National Toll Free Hotline for PET Scans Debuts to Meet Growing Demand for Alzheimer's Diagnosis 1-888-PET-4-YOU SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Due to the rising demand for Positron Emission Tomography (PET) imaging to diagnose Alzheimer's Disease, one of the nation's leading PET service providers, Molecular Imaging Corporation, announced today the launch of a national toll free hotline, 1- 888-PET-4-YOU (1-888-738-4960), to assist people seeking information about PET scans for themselves or loved ones. PET imaging can detect Alzheimer's in the very early stages of the disease, years before traditional outward symptoms of dementia. Early detection makes it possible for doctors to provide treatment therapies that can help slow the progression of Alzheimer's as well as many other diseases. Molecular Imaging Corporation (MIC) provides state-of-the-art molecular imaging services with physicians, hospitals and outpatient clinics in 18 states and providing services at more than 100 locations, MIC has created the hotline to provide information for physicians and patients on how to acquire this diagnostic test as well as help callers locate the nearest PET Imaging center. If callers are from an area in which MIC does not operate, the Company will direct them to talk to their doctor about how to get an evaluation and give them name of the nearest PET diagnostic center chosen from a national database of providers. "PET Imaging can be combined with a careful clinical evaluation to detect Alzheimer's earlier than anything else available. It is important to make sure information about this disease is made available to those Americans who are at risk because of family history and age," said Dr. Mintun, Professor of Radiology, Division of Nuclear Medicine, at Washington University Medical Center in St. Louis, Missouri. "Diagnosis is only the first step, but a key first step. We should not forget that there are treatment options available today for Alzheimer's Disease, and even better treatments are on the way." Positron Emission Tomography (PET) is a molecular medical imaging procedure that shows functional abnormalities based on the metabolism of glucose in tissue. This ability to give a direct measure of the body's metabolic functions gives PET many advantages over other diagnostic imaging techniques. Unlike conventional "anatomic" based imaging procedures like CT, MRI and ultrasound, PET provides "functional" imaging. "Functional Imaging" can detect metabolic changes, which may be precursors to disease. It can monitor response to treatment, as well as eliminate the need for costly redundant testing or invasive surgical procedures. Alzheimer's disease currently affects 4.5 million Americans, and that number is expected to rise dramatically as baby boomers pass the age of 65 and life expectancy continues to rise. It is estimated that one in every ten people over the age of 65 has Alzheimer's disease and 50% of people over the age of 85. It is projected that 27 million Americans will suffer from Alzheimer's by the year 2050. The only affirmative diagnosis for Alzheimer's disease currently is through an autopsy in which the buildup of beta-amyloid plaque is measured in the brain. Because of the difficulty in diagnosing Alzheimer's disease many people who have the disease are not diagnosed until much brain damage has been done. Lengthy exams and multiple tests of cognitive and memory function are required to make the diagnosis in an early stage. However, PET scans, which can be completed in less than 20 minutes, help the clinician make the diagnosis as early as possible -- and that means with a minimum of damage. With the ease and increasing accessibility of PET imaging services, people can begin to take steps to manage the progression of their disease, get their affairs in order, begin existing therapies and participate in new clinical trials. "Over the past few years patients with serious medical disorders and their advocates have begun to understand and appreciate the diagnostic value of a molecular imaging procedure like PET in detecting disease at the earliest stages, many times before symptoms appear," stated Paul J. Crowe, CEO of Molecular Imaging Corporation. "This includes patients with cancer, heart disease and functional disorders like Parkinson's and Alzheimer's. We receive many calls directly from patients or their advocates asking us how and where they can get tested. We explain to them that the first step is for them to speak directly with their family physician about their particular condition, and request the procedure through their physician if it's appropriate for their condition." "Unfortunately, Crowe continued, many physicians are currently not familiar enough with the procedure. Many have not had any personal experience utilizing this new technology or worse don't have access to this imaging technology, and without experience or access to the technology, many patients are never offered the procedure. We have now gone a step further by providing an information hotline that is easily accessible for physicians and their patients." Medicare reimbursement on the way The majority of health benefit insurance companies currently authorizes and pays for molecular imaging diagnostic testing, just as they do for MRI, CT and other radiology procedures, covering cancer, cardiology and neurological disorders, such as Alzheimer's. The Center for Medicare and Medicaid Services (CMS) also currently provides reimbursement for PET for a range of cancer and cardiology testing. Now, after reviewing case studies presented by physician luminaries, and at the request of scores of congressional members, CMS is expected to decide soon whether to reimburse healthcare providers for PET imaging in diagnosing Alzheimer's disease. Should this occur as expected, it will enable millions of senior citizens to be tested for Alzheimer's disease early and regularly. It will also provide an incentive for pharmaceutical companies and research based institutions to develop a cure for this devastating and fatal illness. "The anticipated Medicare reimbursement will make PET imaging more available for the population that needs it most," states Peter S. Conti, M.D., Ph.D., Professor of Radiology, Clinical Pharmacy and Biomedical Engineering at the University of Southern California, as well as Director of the USC PET Science Center. "People over 65 are the fastest growing sector of the population and as the tools for diagnosis, treatment and possible prevention of Alzheimer's grow, it is a logical step to include it in the spectrum of services paid for by Medicare. About Molecular Imaging Corporation Molecular Imaging Corporation (OTC:MLRI) (BULLETIN BOARD: MLRI) is a leading national service provider of Positron Emission Tomography ("PET") diagnostic imaging services. PET is a 3-Dimensional Full Body molecular imaging procedure used to diagnose and stage disease and assess treatment outcomes for many cancers, cardiovascular disease and neurological disorders. The Company operates both mobile and permanent (fixed) PET imaging facilities for hospitals, diagnostic imaging centers and physician groups throughout the U.S. The Company's clinical web site, http://www.petadvances.com/, addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients. The Company's web site, http://www.molecularimagingcorp.com/, addresses questions about the Company's professional services and investor relations. DATASOURCE: Molecular Imaging Corporation CONTACT: Tim Sullivan, +1-212-981-5234, Michael Paluszek +1-212-981-5149, or Wallis Post, +1-212-981-5147, all for Molecular Imaging Corporation Web site: http://www.molecularimagingcorp.com/ http://www.petadvances.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

MLRI Merrill L.Inc